X-linked recessive anhidrotic ectodermal dysplasia with immunodeficiency (XL-EDA-ID) is a developmental and immunologic disorder caused by hypomorphic mutations in the nuclear factor-kB (NF-kB) essential modulator (NEMO) gene on the X chromosome. [1] [2] [3] NEMO is the regulatory subunit of the IkB kinase (IKK) complex, which phosphorylates and degrades NF-kB inhibitor a (IkBa), causing NF-kB activation. Following the identification of amorphic NEMO mutations causing familial incontinentia pigmenti (IP), hypomorphic mutations in NEMO have been identified in XL-EDA-ID patients. Affected boys have sparse hair, eccrine sweat gland dysgenesis, characteristic facies, few, conical teeth and sometimes severe intestinal problems. They are also susceptible to infection with various microorganisms. [1] [2] [3] [4] Stem cell transplantation (SCT) is thought to be the only curative treatment. However, there have been no clinical reports of successful SCT in XL-EDA-ID patients, and most patients die before maturity. In this report, we describe the first successful SCT in an XL-EDA-ID patient, who underwent unrelated umbilical cord blood transplantation (UCBT) after a reduced-intensity conditioning (RIC) regimen.
The patient was a 3-year-old boy. His mother, maternal grandmother and grandmother's sister had been diagnosed with IP. His maternal uncle died from a disorder of unknown etiology when he was 1 month old. At 2 months, the patient had an episode of Klebsiella pneumoniae sepsis and was referred to our hospital. He had mild facial dysmorphy with relative frontal bossing and depressed nasal bridge and had anhidrotic skin. Laboratory examination showed hypogammaglobulinemia, low NK cell activity and high numbers of B cells. A skin biopsy revealed the absence of eccrine sweat glands.
Nucleic acid extracted from peripheral blood mononuclear cells (PBMC) was analyzed for the NEMO mutation. A C insertion was identified at base 1167 in both the patient and his mother (Figure 1 ). Severe clinical courses have been observed in other patients with the same mutation. Three out of five patients with this mutation died of disseminated Mycobacterium avium infection. [1] [2] [3] [4] [5] Flow cytometry analysis 6 showed lower NEMO expression in each PBMC lineage and CD40L induced less upregulation of CD23, CD54, CD86 and CD95 in the patient's cells (Figure 1 ). He was diagnosed as XL-EDA-ID, and biweekly treatment started with intravenous g globulin. Subsequently, the patient had frequent episodes of enterocolitis and Enterobacter aerogenes sepsis. At 2.5 years, he suffered severe pyloric obstruction following enterocolitis. Intestinal endoscopy showed gastric ulcers with nonspecific inflammation and benign colonic polyps. Oral feeding was stopped and the patient started receiving total parenteral nutrition.
The patient did not have an human leucocyte antigen-(HLA-) matched-related or unrelated donor. At 3 years, an unrelated UCBT was performed. Pre-transplant conditioning consisted of fludarabin 30 mg/m 2 on days À7 to À3 (total dose, 150 mg/m 2 ), melpharan 70 mg/m 2 on days À6 to À5 (total dose, 140 mg/m 2 ) and rabbit anti-T-lymphocyte globulin (ATG) 2.5 mg/kg on days À5 to À1 (total dose, 12.5 mg/kg). The patient received 4.6 Â 10 7 total nucleated cells/kg from a male donor. The recipient and donor were one antigen mismatched by serology and four loci mismatched by DNA typing. Tacrolimus (FK506) and short-term methotrexate (MTX) were used for graft-versushost disease (GVHD) prophylaxis. However, MTX was given only on days þ 1 (10 mg/m 2 ) and þ 3 (7 mg/m 2 ), because it caused severe liver toxicity. The conditioning regimen was well tolerated with mild fever caused by ATG. Gastrointestinal toxicity was mild, and total parenteral nutrition was stopped on day þ 39.
Grade I acute GVHD occurred at day þ 35, but resolved without steroid therapy. Neutrophil engraftment (neutrophils40.5 Â 10 9 /l) and platelet engraftment (50 Â 10 9 platelets/l) were documented on days þ 19 and þ 49, respectively. NEMO protein expression was normalized in all PBMC lineages, and cytokine responses to lipopolysaccharide (LPS) and interleukin-18 (IL-18) improved significantly by day þ 156 (Figure 2 ). Mixed chimerism of leukocyte subpopulations purified with immunomagnetic beads were determined by multiplex polymerase chain reaction (PCR) analysis, employing 12 short tandem repeat markers. The results confirmed the patient's full donor chimerism in all lineages on day 105 (data not shown). Twelve months after receiving UCBT, the patient has no sign of chronic GVHD, no symptoms of infections, and he is in perfect performance status.
Most NEMO deficiency patients will have mycobacterial infections or persistent viral infections by young childhood, 4 and these chronic illnesses may impair successful SCT. The excellent treatment course of SCT in this patient may be related to his stable clinical status at the time of SCT, especially the absence of mycobacterial infection. For successful SCT in primary immunodeficiency (PID) patients, it will be essential to find donors before the patients' PBMCs of a normal healthy control and the patient were cultured for 48 h with (thick solid lines) and without (thin dotted lines) recombinant human CD40L as previously described. 6 The histograms of gated CD19 þ cells were shown.
infections become resistant to treatment. 7 The use of umbilical cord blood (UCB) may broaden access to available donors. Recent reports suggest that for PID patients who lack HLA-matched donors, UCB is a more suitable alternative source of hematopoietic stem cells than T-cell depleted haploidentical related marrow. 7 Our experience indicates that UCB may be an ideal source of stem cells for XL-EDA-ID patients.
Unrelated donor SCT with conventional conditioning regimens has been associated with significant treatmentrelated toxicity in PID patients. A recent report showed that the RIC regimen results in improved survival and reduced transplantation-related mortality, compared with myeloablative conditioning in children with PID undergoing SCT. 8 Especially in XL-EDA-ID patients, treatmentrelated toxicity is a great concern for SCT, because NEMO at day 108 after UCBT. There were no lineages detected having subpopulations expressing low NEMO. Open histograms indicate the anti-NEMO mAb, and shaded histograms indicate the isotype controls. (b) Cytokine response to LPS or IL-18 improved significantly at day 156 after UCBT. PBMCs were stimulated with varying doses of IL-18 with IL-12 or varying doses of LPS with interferon-g as described previously. 6 Forty-eight hours later, the supernatant was harvested and the cytokines were measured. mutation impairs NF-kB activity, which is essential for anti-apoptotic response to tumor necrosis factor-a (TNFa). Notably, NEMO-deficient mice are embryonic lethal owing to TNF-induced liver apoptosis. 9 An XL-EDA-ID patient in a previous report, who underwent BMT, died of severe hepatic toxicity shortly after the myeloablative conditioning regimen. 10 That result, together with the observation that our patient developed severe liver dysfunction following low-dose MTX for GVHD prophylaxis, suggests that we cannot exclude the possibility that severe hepatic toxicity in the two patients was due to impaired NF-kB activation, and that the myeloablative conditioning regimen is too toxic for patients with NEMO deficiency.
Our experience shows that correction of immunodeficiency by NEMO mutation is possible by SCT, and UCBT with an RIC regimen can be a suitable therapy for patients with XL-EDA-ID. 
